

## 32-6472: IL 29 Human, His

**Alternative Name :** Interferon lambda-1, IL-29, IL29, IFN-lambda-1, Cytokine Zcyto21, Interleukin-29.

### Description

Source: Escherichia Coli.

Sterile filtered colorless solution.

IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IFN-ambda 1, IFN-lambda 2 and IFN-lambda3 are closely positioned genes on human chromosome 19. IL-29 induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. IL-29 is able to generate tolerogenic DCs, an activity that could thwart IFN-beta functions. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues.

IL 29 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 206 amino acids (20-200 a.a) and having a molecular mass of 22.7kDa. IL 29 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

### Product Info

<b>Amount :</b>	5 µg / 20 µg
<b>Purification :</b>	Greater than 85% as determined by SDS-PAGE.
<b>Content :</b>	IL 29 protein solution (1mg/ml) containing 20mM Tris-HCl (pH8.0) and 10% glycerol.
<b>Storage condition :</b>	Store at 4°C if entire vial will be used within 2-4 weeks.
<b>Amino Acid :</b>	MGSSHHHHHH SSGLVPRGSH MGSHEMGPVPT SKPTTTGKGC HIGRFKSLSP QELASFKKAR DALEESLKLK NWSOSSPVFP GNWDLRLLQV RERPVALEAE LALTLKVLEA AAGPALEDVL DQPLHTLHHI LSQIQACIQP QPTAGPRPRG RLHHWLHRLQ EAPKKESAGC LEASVTFNLF RLLTRDLKYV ADGNLCLRTS THPEST.